Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia

Abstract: Peripheral neuropathy (PN) is a significant cause of morbidity associated with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of zanubrutinib with ibrutinib in patients with WM. This ad hoc analysis examined treatment outcomes with zanubrutinib...

Descripció completa

Dades bibliogràfiques

Autors principals:	Benjamin M. Heyman, Stephen S. Opat, Björn E. Wahlin, Meletios-Athanasios C. Dimopoulos, Jorge J. Castillo, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G. Owen, Véronique Leblond, Judith Trotman, Gisoo Barnes, Wai Y. Chan, Jingjing Schneider, Heather Allewelt, Aileen Cohen, Jeffrey V. Matous
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-02-01
Col·lecció:	Blood Advances
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2473952924006931
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!